BCL2L1 and cancer: Similarly, olaparib-induced TIS in BRCA1-deficient cancer cells—a model of transient, unprimed senescence—shows remarkable sensitivity to A1331852, further highlighting the versatility of BCL-xL-targeted senolytics against mechanistically heterogeneous TIS states.